Keiretsu Forum Mid-Atlantic, South-East, and Texas regions are excited to announce their sponsorship of CRISPR QC at the Innovation Funders Showcase during the 2024 Angel Capital Association (ACA) Summit. This partnership underscores Keiretsu Forum's commitment to advancing cutting-edge technologies in the rapidly evolving field of gene editing.
Accelerating Gene Editing Innovations
CRISPR QC has developed an innovative tool called the CRISPR Analytics Platform, which significantly improves the process of gene editing. The heart of this technology is the CRISPR-Chip, which can accurately predict how well the gene editing will work. This platform combines robotics and smart algorithms to precisely measure and enhance gene-editing techniques, making it faster and more reliable to develop new genetic solutions.
CRISPR QC has made significant strides in the first quarter of 2024, focusing on commercial advancements that streamline and enhance gene editing workflows. With the recent addition of industry veterans Tim Cloutier as Chief Commercial Officer and Susan Pede as Vice President of Operations, CRISPR QC is poised for rapid growth. Their efforts have already resulted in an increase in customer project turnaround and the development of a robust commercial strategy.
Customized Solutions for Complex Challenges
CRISPR QC addresses unique challenges in the gene editing sector by implementing a customer-centric approach, which includes targeted marketing, pilot studies, and comprehensive service offerings that lead to large-scale enterprise solutions. This strategy not only educates clients about unrecognized problems but also tailors solutions to specific workflow needs, enhancing overall efficiency and effectiveness.
A Promising Future with Strategic Expansion
Looking ahead, CRISPR QC plans to launch three new products by the end of 2024, based on insights gathered from pilot programs. These products are expected to propel more customers into the pilot phase, further solidifying CRISPR QC's position as a leader in the gene editing
market. Additionally, the company has successfully engaged a significant audience through targeted content marketing campaigns, indicating strong market interest.
About CRISPR QC
CRISPR QC is dedicated to optimizing gene editing workflows through innovative technologies and services. Their approach includes a step-by-step customer journey that encompasses marketing, pilot studies, workflow optimization, and comprehensive SaaS solutions, aiming to revolutionize the gene editing process by 2026.
About Keiretsu Forum Mid-Atlantic, South-East, and Texas
Keiretsu Forum is the world’s largest private equity angel investment network, with over 2,000 accredited investors across 34 North American and 23 International chapters. They have invested more than $1 billion in various sectors, including technology, life sciences, and consumer products, over the last 23 years.
The ACA Summit, scheduled to take place in Columbus, Ohio from May 13-15, 2024, will provide a vital platform for networking, innovation, and investment opportunities in the dynamic field of biotechnology.
For more information on the ACA Summit and CRISPR QC's participation, please contact:
Cindi Sutera
AMS Communications
cindis@amscommunications.net
610-613-2773